Mariana Brandao
@marianabrandao0.bsky.social
Thoracic medical oncologist & researcher @JulesBordet & associate professor @ULB in #Brussels 🇧🇪 working in #lungcancer #neutrophils #translationalresearch #phase1 & #globalhealth
Reposted by Mariana Brandao
Today on #WorldCancerDay we're proud to support our 13K members worldwide as they work on the fundamental research that leads to treatment breakthroughs. #UnitedbyUnique
February 4, 2025 at 9:26 AM
Today on #WorldCancerDay we're proud to support our 13K members worldwide as they work on the fundamental research that leads to treatment breakthroughs. #UnitedbyUnique
What's the Land of Tomorrow of #IO in #NSCLC?
At #ESMOImmune2024 I had the honor to discuss the data on
🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high
🔴 Inupadenant +carbo/pem after IO failure
🔴 Effectiveness & immunophenotype in orphan genomic alterations
@oncoalert.bsky.social #lcsm
At #ESMOImmune2024 I had the honor to discuss the data on
🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high
🔴 Inupadenant +carbo/pem after IO failure
🔴 Effectiveness & immunophenotype in orphan genomic alterations
@oncoalert.bsky.social #lcsm
December 13, 2024 at 1:39 PM
What's the Land of Tomorrow of #IO in #NSCLC?
At #ESMOImmune2024 I had the honor to discuss the data on
🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high
🔴 Inupadenant +carbo/pem after IO failure
🔴 Effectiveness & immunophenotype in orphan genomic alterations
@oncoalert.bsky.social #lcsm
At #ESMOImmune2024 I had the honor to discuss the data on
🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high
🔴 Inupadenant +carbo/pem after IO failure
🔴 Effectiveness & immunophenotype in orphan genomic alterations
@oncoalert.bsky.social #lcsm
Exciting data at #ESMOImmumo2024 showed by George Coukos on adoptive immune cell therapies:
🔵 Nb of reactive antitumor TILs that are injected correlate with response
🔵 How to improve #TIL treatments in pts with #melanoma
@oncoalert.bsky.social
🔵 Nb of reactive antitumor TILs that are injected correlate with response
🔵 How to improve #TIL treatments in pts with #melanoma
@oncoalert.bsky.social
December 13, 2024 at 10:06 AM
Exciting data at #ESMOImmumo2024 showed by George Coukos on adoptive immune cell therapies:
🔵 Nb of reactive antitumor TILs that are injected correlate with response
🔵 How to improve #TIL treatments in pts with #melanoma
@oncoalert.bsky.social
🔵 Nb of reactive antitumor TILs that are injected correlate with response
🔵 How to improve #TIL treatments in pts with #melanoma
@oncoalert.bsky.social
How to counteract the immunosuppressive action of #adenosine in #TNBC?
@laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪
@oncoalert.bsky.social #ESMOImmuno2024
@laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪
@oncoalert.bsky.social #ESMOImmuno2024
December 13, 2024 at 8:35 AM
How to counteract the immunosuppressive action of #adenosine in #TNBC?
@laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪
@oncoalert.bsky.social #ESMOImmuno2024
@laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪
@oncoalert.bsky.social #ESMOImmuno2024
Reposted by Mariana Brandao
When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!
December 12, 2024 at 2:58 PM
When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!
Reposted by Mariana Brandao
Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!
December 12, 2024 at 2:42 PM
Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!
Reposted by Mariana Brandao
🧑⚕️ Calling #YoungOncologists - Have an idea for a trial or study? The annual #MCCRWorkshop now open for applications!
🗓️ Deadline 31 Jan 2025
@mcrcnews.bsky.social
🔗 ow.ly/2KEB50UohRW
🗓️ Deadline 31 Jan 2025
@mcrcnews.bsky.social
🔗 ow.ly/2KEB50UohRW
December 12, 2024 at 10:34 AM
🧑⚕️ Calling #YoungOncologists - Have an idea for a trial or study? The annual #MCCRWorkshop now open for applications!
🗓️ Deadline 31 Jan 2025
@mcrcnews.bsky.social
🔗 ow.ly/2KEB50UohRW
🗓️ Deadline 31 Jan 2025
@mcrcnews.bsky.social
🔗 ow.ly/2KEB50UohRW
Reposted by Mariana Brandao
Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC.
clinicaltrials.gov/study/NCT064...
#bcsm
clinicaltrials.gov/study/NCT064...
#bcsm
December 3, 2024 at 10:42 AM
Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC.
clinicaltrials.gov/study/NCT064...
#bcsm
clinicaltrials.gov/study/NCT064...
#bcsm
Reposted by Mariana Brandao
💥40 years ago today a 33 y/o dying of #metastatic #melanoma got #LAK & #IL-2 & all #cancer went away! Dr. S.A. #Rosenberg (SAR) had the #immune system #cure a patient/I was in SAR’s lab 85-90/incredible era & energy/Great story in @usatoday.com apple.news/AIcm-M7cDQ-O... @sitcancer.bsky.social
Opinion | Her medical file read 'death imminent.' His treatment plan changed cancer forever. | Opinion — USA TODAY
Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully used it to save a life.
apple.news
November 30, 2024 at 1:32 AM
💥40 years ago today a 33 y/o dying of #metastatic #melanoma got #LAK & #IL-2 & all #cancer went away! Dr. S.A. #Rosenberg (SAR) had the #immune system #cure a patient/I was in SAR’s lab 85-90/incredible era & energy/Great story in @usatoday.com apple.news/AIcm-M7cDQ-O... @sitcancer.bsky.social
Congratulations @mattiarediti.bsky.social & Christos Sotiriou for this extraordinary work on HER2+ breast cancer!! 💪👏👏
Our work on HER2+ breast cancer heterogeneity (from my PhD with Christos Sotiriou at the Institut Jules Bordet) is out @naturecomms.bsky.social
➡️5 molecular subtypes 🧬 identified in the ALTTO trial with external validations
Grateful to Christos and all co-Authors
www.nature.com/articles/s41...
➡️5 molecular subtypes 🧬 identified in the ALTTO trial with external validations
Grateful to Christos and all co-Authors
www.nature.com/articles/s41...
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial - Nature Communications
The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...
www.nature.com
November 29, 2024 at 7:46 PM
Congratulations @mattiarediti.bsky.social & Christos Sotiriou for this extraordinary work on HER2+ breast cancer!! 💪👏👏
Reposted by Mariana Brandao
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
academic.oup.com
November 29, 2024 at 2:16 PM
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
Reposted by Mariana Brandao
⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social
mdpi.com/3031120
mdpi.com/3031120
Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
Introduction: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, despite advances in immune checkpoint inhibitors and targeted therapies. Antibody–drug c...
mdpi.com
November 29, 2024 at 3:16 PM
⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social
mdpi.com/3031120
mdpi.com/3031120
Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
November 29, 2024 at 4:00 PM
Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨
🔴How ADCs are made?
🔴What mechanisms of resistance?
🔴How to improve efficacy?
@oncoalert.bsky.social
Reposted by Mariana Brandao
🧑🔬🏛️👩⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky
#StarterPack 1 is already full 🙌, so starting a another one.
Let's continue growing!
- Pack 1️⃣: go.bsky.app/PRdmHCP
- Pack 2️⃣: go.bsky.app/93eqJbs
#StarterPack 1 is already full 🙌, so starting a another one.
Let's continue growing!
- Pack 1️⃣: go.bsky.app/PRdmHCP
- Pack 2️⃣: go.bsky.app/93eqJbs
November 25, 2024 at 6:18 PM
🧑🔬🏛️👩⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky
#StarterPack 1 is already full 🙌, so starting a another one.
Let's continue growing!
- Pack 1️⃣: go.bsky.app/PRdmHCP
- Pack 2️⃣: go.bsky.app/93eqJbs
#StarterPack 1 is already full 🙌, so starting a another one.
Let's continue growing!
- Pack 1️⃣: go.bsky.app/PRdmHCP
- Pack 2️⃣: go.bsky.app/93eqJbs
Don't miss the next #ESMO Virtual Journal Club on Wed 4/Dec🔎📃 we'll discuss:
#LAURA trial: Osi after CRT in #NSCLC 🫁
#RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer
🚨Don't forget to register! 👇
@oncoalert.bsky.social
#LAURA trial: Osi after CRT in #NSCLC 🫁
#RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer
🚨Don't forget to register! 👇
@oncoalert.bsky.social
ESMO Virtual Journal Club: December 2024
This ESMO Webinar Series is available to all ESMO Members
www.esmo.org
November 25, 2024 at 5:04 PM
Don't miss the next #ESMO Virtual Journal Club on Wed 4/Dec🔎📃 we'll discuss:
#LAURA trial: Osi after CRT in #NSCLC 🫁
#RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer
🚨Don't forget to register! 👇
@oncoalert.bsky.social
#LAURA trial: Osi after CRT in #NSCLC 🫁
#RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer
🚨Don't forget to register! 👇
@oncoalert.bsky.social
Reposted by Mariana Brandao
18th edition of the Belgian Symposium on the Integration of Molecular Biology -
Friday 29/11 and Saturday 30/11/2024
Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network
www.bordet.be/fr/18th-edit...
Friday 29/11 and Saturday 30/11/2024
Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network
www.bordet.be/fr/18th-edit...
November 13, 2024 at 11:58 AM
18th edition of the Belgian Symposium on the Integration of Molecular Biology -
Friday 29/11 and Saturday 30/11/2024
Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network
www.bordet.be/fr/18th-edit...
Friday 29/11 and Saturday 30/11/2024
Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network
www.bordet.be/fr/18th-edit...
Reposted by Mariana Brandao
Institut Jules Bordet (part of the) medical oncology team dinner 🤗
@mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!
@mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!
November 23, 2024 at 3:22 PM
Institut Jules Bordet (part of the) medical oncology team dinner 🤗
@mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!
@mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!